Literature DB >> 12935964

Acute promyelocytic leukaemia in children.

John Gregory1, James Feusner.   

Abstract

Acute promyelocytic leukaemia (APL), designated M3, is a particularly interesting subtype of acute myeloid leukaemia (AML) that has unique molecular and clinical characteristics. It is characterized by an arrest of myeloid differentiation at the promyelocyte stage with abnormal proliferation of these cells. Recent paediatric and adult trials which included all-trans retinoic acid (ATRA) have shown that APL has significantly better survival rates than other subtypes of AML. While there is extensive literature on APL in adults, articles dedicated to describing solely paediatric patients are limited. This chapter focuses on the incidence, diagnosis, clinical characteristics, treatment, and survival rates of children with APL.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12935964     DOI: 10.1016/s1521-6926(03)00060-4

Source DB:  PubMed          Journal:  Best Pract Res Clin Haematol        ISSN: 1521-6926            Impact factor:   3.020


  4 in total

Review 1.  How I treat children and adolescents with acute promyelocytic leukaemia.

Authors:  Oussama Abla; Raul C Ribeiro
Journal:  Br J Haematol       Date:  2013-09-30       Impact factor: 6.998

2.  Nephrotic-range proteinuria in a child with retinoic acid syndrome.

Authors:  Christine B Sethna; Kiranmye Reddy; Carolyn Fein-Levy; Howard Trachtman
Journal:  Pediatr Nephrol       Date:  2011-11-13       Impact factor: 3.714

3.  Hematopoietic stem cell transplant for pediatric acute promyelocytic leukemia.

Authors:  Christopher C Dvorak; Rajni Agarwal; Gary V Dahl; John J Gregory; James H Feusner
Journal:  Biol Blood Marrow Transplant       Date:  2008-07       Impact factor: 5.742

Review 4.  Acute Promyelocytic Leukemia (APL): Comparison Between Children and Adults.

Authors:  Anna Maria Testi; Mariella D'Angiò; Franco Locatelli; Andrea Pession; Francesco Lo Coco
Journal:  Mediterr J Hematol Infect Dis       Date:  2014-04-15       Impact factor: 2.576

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.